

Ephrin Type B Receptor 4 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/E3EEC442CAB7EN.html>

Date: November 2019

Pages: 45

Price: US\$ 3,500.00 (Single User License)

ID: E3EEC442CAB7EN

Abstracts

Ephrin Type B Receptor 4 - Pipeline Review, H2 2019

SUMMARY

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The latest report Ephrin Type B Receptor 4 - Pipeline Review, H2 2019, outlays comprehensive information on the Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Ephrin type-B receptor 4 is a protein encoded by the EPHB4 gene. It binds promiscuously to transmembrane ephrin-B family ligands residing on adjacent cells which lead to contact dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. It plays a central role in heart morphogenesis and angiogenesis through regulation of cell adhesion and cell migration. It plays an important role in postnatal blood vessel remodeling, morphogenesis and permeability. The molecules developed by companies in Phase II stages are 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders and Infectious Disease which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct

Cancer (Cholangiocarcinoma), Bladder Cancer, Colorectal Cancer, Gallbladder Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hypopharyngeal Cancer, Kaposi Sarcoma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Malignant Pleural Mesothelioma, Metastatic Brain Tumor, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Oropharyngeal Cancer, Pancreatic Cancer, Polycystic Kidney Disease, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.

Furthermore, this report also reviews key players involved in Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1)

The report reviews Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ephrin Type

B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Overview

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Kadmon Corp LLC

VasGene Therapeutics Inc

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Drug Profiles

Small Molecule to Inhibit VEGFR2, TIE 2 and EPHB4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize EphB4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize EphB4 Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesevatinib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vas-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VDAU-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Dormant Products

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Nov 13, 2017: Kadmon Initiates Phase 2 Placebo-Controlled Clinical Trial of Tesevatinib in Autosomal Dominant Polycystic Kidney Disease

Aug 07, 2017: FDA Grants Orphan Drug Designation to Kadmon's Tesevatinib for the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Dec 06, 2016: Kadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases

Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016

Aug 29, 2016: Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma

Dec 18, 2015: Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Non-Small Cell Lung Cancer with Activating EGFR Mutations and Brain Metastases or Leptomeningeal Disease

Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015

May 28, 2015: Kadmon Announces Initial Phase 1b Data for Tesevatinib in Patients With Metastatic Breast Cancer

Apr 20, 2015: Kadmon Presents Encouraging Nonclinical Data on Tesevatinib (KD019) at AACR Annual Meeting

Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease

Jun 04, 2014: Kadmon Announces the Initiation of a Phase 1b/2a Study of KD019 and Trastuzumab in HER2-Positive Metastatic Breast Cancer

Apr 07, 2014: Kadmon Presents Preclinical Results Demonstrating KD019 Activity in

Trastuzumab Resistant HER2+ Breast Cancer

Oct 24, 2012: Kadmon Doses First Patient In Phase Ib/IIa Study Of KD020 In Polycystic Kidney Disease

Feb 27, 2012: Biodesix Collaborates With Kadmon For Phase III Clinical Trial Of KD019

Jun 02, 2008: Exelixis Reports Phase 1 And Phase 2 Data For XL647 At ASCO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Kadmon Corp LLC, H2 2019
Pipeline by VasGene Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Kadmon Corp LLC

VasGene Therapeutics Inc

I would like to order

Product name: Ephrin Type B Receptor 4 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/E3EEC442CAB7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E3EEC442CAB7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970